
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1169708/publications.pdf Version: 2024-02-01



LIAN-CAO FAN

#	Article	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
2	New trends on obesity and NAFLD in Asia. Journal of Hepatology, 2017, 67, 862-873.	3.7	759
3	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Journal of Hepatology, 2017, 66, 1022-1030.	3.7	734
4	Epidemiology of non-alcoholic fatty liver disease in China. Journal of Hepatology, 2009, 50, 204-210.	3.7	444
5	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 2020, 14, 889-919.	4.2	422
6	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. Journal of Digestive Diseases, 2011, 12, 38-44.	1.5	227
7	Lipotoxic Hepatocyteâ€Derived Exosomal MicroRNA 192â€5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 454-469.	7.3	170
8	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	8.1	135
9	Role of diet and nutritional management in nonâ€ e lcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 81-87.	2.8	127
10	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). Journal of Digestive Diseases, 2019, 20, 163-173.	1.5	111
11	Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nature Communications, 2019, 10, 623.	12.8	95
12	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology, 2014, 20, 4702.	3.3	92
13	β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Molecular Medicine Reports, 2014, 9, 2145-2151.	2.4	86
14	Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2015, 16, 5161-5179.	4.1	81
15	circRNA_0046367 Prevents Hepatoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-16.	4.0	77
16	Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors. Digestive Diseases and Sciences, 2014, 59, 2571-2579.	2.3	74
17	circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World Journal of Gastroenterology, 2018, 24, 323-337.	3.3	72
18	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver International, 2015, 35, 2392-2400.	3.9	71

#	Article	lF	CITATIONS
19	NAFLD leads to liver cancer: Do we have sufficient evidence?. Cancer Letters, 2014, 345, 230-234.	7.2	54
20	Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis. BioMed Research International, 2017, 2017, 1-13.	1.9	50
21	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	4.4	49
22	Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary and Pancreatic Diseases International, 2009, 8, 233-40.	1.3	47
23	Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Translational Research, 2017, 180, 103-117.e4.	5.0	46
24	Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian Medicine, 2016, 19, 197-203.	0.6	45
25	Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. Medical Science Monitor, 2015, 21, 2476-2484.	1.1	40
26	Prevention of hepatocellular carcinoma in nonviralâ€related liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 712-719.	2.8	35
27	Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Alimentary Pharmacology and Therapeutics, 2019, 50, 93-102.	3.7	35
28	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 2022, 20, 2296-2306.e6.	4.4	35
29	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS ONE, 2016, 11, e0155934.	2.5	34
30	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2020, 26, 1792-1804.	3.3	34
31	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 2719-2731.	3.9	32
32	Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection With Nonalcoholic Fatty Liver Disease by Toll-Like Receptor 4-Mediated Innate Immune Response. Hepatitis Monthly, 2015, 15, e27909.	0.2	30
33	Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Scientific Reports, 2015, 5, 13980.	3.3	29
34	High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma. BMC Gastroenterology, 2014, 14, 195.	2.0	25
35	What are the clinical settings and outcomes of lean NAFLD?. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 289-290.	17.8	24
36	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 154-161.	1.3	24

#	Article	IF	CITATIONS
37	APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. Digestive Diseases and Sciences, 2016, 61, 2284-2293.	2.3	22
38	The gut mycobiome: a novel player in chronic liver diseases. Journal of Gastroenterology, 2021, 56, 1-11.	5.1	22
39	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2021, 12, e00323.	2.5	22
40	Linked <i>PNPLA3</i> polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World Journal of Gastroenterology, 2015, 21, 8605.	3.3	21
41	Thyroid function is associated with nonâ€alcoholic fatty liver disease in chronic hepatitis <scp>B</scp> â€infected subjects. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1753-1758.	2.8	20
42	Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak. Journal of Clinical and Translational Hepatology, 2022, 10, 522-530.	1.4	19
43	Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B. Scientific Reports, 2017, 7, 10517.	3.3	18
44	Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic. Current Cancer Drug Targets, 2017, 17, 505-511.	1.6	17
45	Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells. BioMed Research International, 2015, 2015, 1-11.	1.9	16
46	Guidelines of prevention and treatment for alcoholic liver disease (2018, China). Journal of Digestive Diseases, 2019, 20, 174-180.	1.5	16
47	RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. International Journal of Clinical and Experimental Pathology, 2014, 7, 1085-92.	0.5	14
48	Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation. Experimental and Therapeutic Medicine, 2016, 12, 1345-1348.	1.8	12
49	Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease. International Journal of Molecular Medicine, 2018, 42, 443-452.	4.0	12
50	Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ. Experimental and Therapeutic Medicine, 2017, 13, 780-786.	1.8	11
51	Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. Medicine (United States), 2019, 98, e17098.	1.0	10
52	Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis. Archives of Iranian Medicine, 2014, 17, 563-8.	0.6	10
53	Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacologica Sinica, 2022, 43, 941-953.	6.1	9
54	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World Journal of Gastroenterology, 2020, 26, 2416-2426.	3.3	9

#	Article	IF	CITATIONS
55	The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncology Letters, 2016, 12, 951-955.	1.8	8
56	Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a highâ€fat, highâ€cholesterol diet. Journal of Digestive Diseases, 2020, 21, 179-188.	1.5	7
57	Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research. Current Stem Cell Research and Therapy, 2015, 10, 208-215.	1.3	7
58	APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. BioMed Research International, 2020, 2020, 1-9.	1.9	6
59	Nonâ€alcoholic fatty liver disease to metabolic dysfunctionâ€associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. Journal of Digestive Diseases, 2020, 21, 604-609.	1.5	5
60	Simple nonâ€invasive scoring systems and histological scores in predicting mortality in patients with nonâ€elcoholic fatty liver disease: A systematic review and metaâ€enalysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1754-1768.	2.8	5
61	Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. World Journal of Gastroenterology, 2022, 28, 1681-1691.	3.3	5
62	PNPLA3rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism. Journal of Diabetes Research, 2017, 2017, 1-12.	2.3	4
63	Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth. Frontiers in Endocrinology, 2021, 12, 805722.	3.5	4
64	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 1-3.	1.3	2
65	Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	2
66	Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?. Clinical and Molecular Hepatology, 2022, 28, 473-477.	8.9	2
67	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B—authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 334-335.	3.7	1
68	Multidisciplinary participation: the key to cure for nonâ€alcoholic fatty liver disease. Journal of Digestive Diseases, 2021, , .	1.5	1
69	Editorial: opposite effects of genetic polymorphisms known to induce <scp>NAFLD</scp> on hepatic and cardiovascular outcomes in Chinese population. Alimentary Pharmacology and Therapeutics, 2022, 55, 876-877.	3.7	1
70	A tribute to Dr Guang-bi Yao (1931-2010). Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1027-1028.	2.8	0
71	Letter: moderateâ€toâ€severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 617-618.	3.7	0